JPH0332356B2 - - Google Patents
Info
- Publication number
- JPH0332356B2 JPH0332356B2 JP58118809A JP11880983A JPH0332356B2 JP H0332356 B2 JPH0332356 B2 JP H0332356B2 JP 58118809 A JP58118809 A JP 58118809A JP 11880983 A JP11880983 A JP 11880983A JP H0332356 B2 JPH0332356 B2 JP H0332356B2
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- thrombolytic
- amino acid
- basic amino
- alkyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003146 anticoagulant agent Substances 0.000 claims description 31
- 230000002537 thrombolytic effect Effects 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 25
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 25
- 229960005356 urokinase Drugs 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 125000005907 alkyl ester group Chemical group 0.000 claims description 17
- 229920002307 Dextran Polymers 0.000 claims description 16
- 150000004676 glycans Chemical class 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical compound [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- -1 etc. Chemical compound 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960000103 thrombolytic agent Drugs 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- ZDLDXNCMJBOYJV-YFKPBYRVSA-N L-arginine, methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N ZDLDXNCMJBOYJV-YFKPBYRVSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58118809A JPS6011427A (ja) | 1983-06-29 | 1983-06-29 | 血栓溶解性蛋白の疾患局所親和性向上方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58118809A JPS6011427A (ja) | 1983-06-29 | 1983-06-29 | 血栓溶解性蛋白の疾患局所親和性向上方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6011427A JPS6011427A (ja) | 1985-01-21 |
| JPH0332356B2 true JPH0332356B2 (enrdf_load_stackoverflow) | 1991-05-10 |
Family
ID=14745661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58118809A Granted JPS6011427A (ja) | 1983-06-29 | 1983-06-29 | 血栓溶解性蛋白の疾患局所親和性向上方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6011427A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084274A (en) * | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
-
1983
- 1983-06-29 JP JP58118809A patent/JPS6011427A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6011427A (ja) | 1985-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4055635A (en) | Fibrinolytic compositions | |
| US4640835A (en) | Plasminogen activator derivatives | |
| JP2537602B2 (ja) | 安定性タンパク質及びタンパク質の安定化法 | |
| US5969040A (en) | Factor IX -- polymeric conjugates | |
| JP3398150B2 (ja) | 新規接合体、その調製および使用ならびにその接合体を用いて調製された基体 | |
| US5705153A (en) | Glycolipid enzyme-polymer conjugates | |
| DE69015182T2 (de) | Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. | |
| JPH0525470B2 (enrdf_load_stackoverflow) | ||
| EP0620738A1 (en) | Fibrinolysis and fibrinogenolysis treatment with plasmin | |
| US7172760B2 (en) | Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots | |
| JPH09110715A (ja) | 血液凝固疾患を治療するための医薬組成物とその製造法 | |
| WO1993007893A1 (en) | Fibrinolysis and fibrinogenolysis treatment with plasmin | |
| Boccù et al. | Coupling of monomethoxypolyethyleneglycols to proteins via active esters | |
| JP2978187B2 (ja) | 修飾スーパーオキサイドディスムターゼの製造法 | |
| JPH02504587A (ja) | ７ａ因子に富む画分の製造方法及び医薬としてのその用途 | |
| JP2001523648A (ja) | ２種の活性剤を含むコンジュゲート | |
| JP2001081103A (ja) | ヒアルロン酸結合薬剤 | |
| JPH0332356B2 (enrdf_load_stackoverflow) | ||
| Poznansky | Enzyme-protein conjugates: new possibilities for enzyme therapy | |
| JPS6360938A (ja) | 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法 | |
| Kim et al. | Immobilization of urokinase on agarose matrices | |
| US20060147441A1 (en) | Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field | |
| JPS59118717A (ja) | プラスミノーゲン活性化剤 | |
| JPH0215193B2 (enrdf_load_stackoverflow) | ||
| JPH06293631A (ja) | ケラチン加水分解物を担体として用いたドラッグデリバリーシステム |